4,4-Difluoro-N-[(1S)-3-hydroxy-1-phenylpropyl]cyclohexanecarboxamide

We are 4,4-Difluoro-N-[(1S)-3-hydroxy-1-phenylpropyl]cyclohexanecarboxamide CAS:376348-77-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name: 4,4-Difluoro-N-[(1S)-3-hydroxy-1-phenylpropyl]cyclohexanecarboxamide
Synonym: (S)-4,4-difluoro-N-(3-hydroxy-1-phenylpropyl)cyclohexanecarboxamide; Intermediate of Maraviroc
Cas No.: 376348-77-5
Formula: C₁₆H₂₁F₂NO₂
MW: 297.34
EINECS No.: 638-778-4

HS Code: 2903890090

UN No.: N.A
Hazard class: Non-dangerous goods
 
Specification

Items of Analysis	Standard of Analysis	Test Results
Appearance	White or similar white powder	Conforms
Purity (HPLC)	≥99%	99.75%
Single Impurity	≤1.0%	0.07%
Total impurities	≤1.0%	0.25%
Loss on drying	≤0.5%	0.12%
Residue on Ignition	≤0.15%	0.13%
Conclusion	Conforms to Factory Standard

 
 
Application
Intermediate of Maraviroc.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 




Related News: Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.6-hydroxy-7-methoxy-1H-quinazolin-4-one CAS:179688-52-9 Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.877384-16-2 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).In the TOP50 list of API export companies in 2017, the geographical clustering of advantageous companies is still obvious. For example, Huahai and Pluo in Zhejiang, CSPC of Hebei, Xinhua Pharmaceutical and Xinfa Pharmaceutical of Shandong rank well. Rank.